Replies to post #14195 on Aurinia Pharmaceuticals Inc (AUPH)

[puravida]

one thing is for sure BMY has a shit ton of cash flow and the forecasts aren't going anywhere for them. and money is still cheap so a company with that kind of cash flow stats (50B range) has a buffet of options for low risk financing. remind that when J&J acquired Momenta for 6.5B which closed just over a year ago, I laughed when I read that their cash war chest wasn't even touched as the entire deal was completed with low risk loans. These big Pharma companies, BMY...all of them.....they have plenty of options and war chests. any BP CEO that doesn't prioritize M&A in the near future is gonna pay for that missed opportunity...Caforio certainly didn't waste any time yesterday to spread the word that small to medium bio bolt-ons were on the top of his list for strategy